Galderma's record H1 performance is partly fueled by an unexpected tailwind: the GLP-1 weight loss drug boom. As patients on semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound, Mounjaro) shed pounds, many are seeking facial rejuvenation to address volume loss, skin laxity, and the hollowed appearance colloquially known as "Ozempic face."
Market
Galderma Capitalizes on GLP-1 Weight Loss Trend—What Practices Should Know
Rising demand for facial rejuvenation among patients on semaglutide and tirzepatide is driving injectable volume.
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
GLP-1 patients seeking facial rejuvenation are driving incremental demand for fillers and neuromodulators.
This demographic shift is driving incremental demand for neuromodulators and volumizing fillers—exactly Galderma's strength. Practices with strong filler protocols and a patient base skewing toward weight-loss-conscious demographics are seeing elevated per-patient treatment frequency. The trend underscores the importance of having robust HA and biostimulator inventory and trained staff to counsel on combination protocols addressing both dynamic lines and structural volume loss.
Source: original report ↗
Frequently asked questions
What is Ozempic face and why are patients seeking treatment for it?
Ozempic face refers to the hollowed, gaunt appearance that can result from rapid weight loss on GLP-1 drugs like semaglutide and tirzepatide. Patients are seeking facial rejuvenation treatments to address volume loss, skin laxity, and facial hollowing caused by these medications.
Which injectables are most in demand from GLP-1 patients?
Neuromodulators and volumizing fillers are seeing the highest demand from this demographic. Practices should prioritize robust inventory of hyaluronic acid (HA) fillers and biostimulators to meet the increased treatment frequency in this patient segment.
How should practices adjust their protocols for GLP-1 weight loss patients?
Practices should develop combination protocols that address both dynamic lines and structural volume loss, requiring trained staff to counsel patients on integrated treatment plans. This approach capitalizes on the elevated per-patient treatment frequency observed in weight-loss-conscious demographics.
What GLP-1 drugs are driving the demand for facial aesthetics?
Semaglutide (brand names Ozempic and Wegovy) and tirzepatide (brand names Zepbound and Mounjaro) are the primary drivers of this trend. As patients on these medications experience significant weight loss, they're seeking facial rejuvenation services.
Is the GLP-1 trend boosting revenue for aesthetic companies like Galderma?
Yes—Galderma reported record H1 performance partly fueled by increased demand for injectables from GLP-1 patients. This demographic shift is driving incremental injectable volume and higher per-patient treatment frequency for practices positioned to serve this market.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.